152 related articles for article (PubMed ID: 1899798)
1. Effect of deficiencies in DNA repair on the toxicity of mitomycin C and porfiromycin to CHO cells under aerobic and hypoxic conditions.
Hughes CS; Irvin CG; Rockwell S
Cancer Commun; 1991 Feb; 3(2):29-35. PubMed ID: 1899798
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells.
Fracasso PM; Sartorelli AC
Cancer Res; 1986 Aug; 46(8):3939-44. PubMed ID: 3089583
[TBL] [Abstract][Full Text] [Related]
3. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells.
Marshall RS; Rauth AM
Cancer Res; 1988 Oct; 48(20):5655-9. PubMed ID: 3167822
[TBL] [Abstract][Full Text] [Related]
4. Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1989 Jun; 49(12):3310-3. PubMed ID: 2470504
[TBL] [Abstract][Full Text] [Related]
5. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1985 Aug; 45(8):3642-5. PubMed ID: 3926306
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
Kim SY; Rockwell S
Oncol Res; 1995; 7(5):39-47. PubMed ID: 8534933
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic potential of monoalkylation products between mitomycins and DNA: studies of decarbamoyl mitomycin C in wild-type and repair-deficient cell lines.
Rockwell S; Kim SY
Oncol Res; 1995; 7(1):39-47. PubMed ID: 7549043
[TBL] [Abstract][Full Text] [Related]
8. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant.
Marshall RS; Rauth AM
Cancer Res; 1986 Jun; 46(6):2709-13. PubMed ID: 3084075
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase.
Dulhanty AM; Whitmore GF
Cancer Res; 1991 Apr; 51(7):1860-5. PubMed ID: 1900739
[TBL] [Abstract][Full Text] [Related]
10. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH:cytochrome c (P-450) reductase.
Belcourt MF; Hodnick WF; Rockwell S; Sartorelli AC
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):456-60. PubMed ID: 8552660
[TBL] [Abstract][Full Text] [Related]
11. DNA repair mechanisms are involved in the hypoxia-dependent toxicity of NLCQ-1 (NSC 709257) and its synergistic interaction with alkylating agents.
Papadopoulou MV; Bloomer WD
In Vivo; 2007; 21(2):175-80. PubMed ID: 17436565
[TBL] [Abstract][Full Text] [Related]
12. Effect of the superoxide dismutase inhibitor, diethyldithiocarbamate, on the cytotoxicity of mitomycin antibiotics.
Pritsos CA; Keyes SR; Sartorelli AC
Cancer Biochem Biophys; 1989 Oct; 10(4):289-98. PubMed ID: 2559790
[TBL] [Abstract][Full Text] [Related]
13. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo.
Rauth AM; Mohindra JK; Tannock IF
Cancer Res; 1983 Sep; 43(9):4154-8. PubMed ID: 6409398
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.
Palmer BD; Wilson WR; Anderson RF; Boyd M; Denny WA
J Med Chem; 1996 Jun; 39(13):2518-28. PubMed ID: 8691449
[TBL] [Abstract][Full Text] [Related]
15. Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells.
Keyes SR; Rockwell S; Sartorelli AC
Cancer Res; 1987 Nov; 47(21):5654-7. PubMed ID: 3664473
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mitomycin C's aerobic toxicity by the seleno-organic antioxidant PZ-51.
Gustafson DL; Pritsos CA
Cancer Chemother Pharmacol; 1991; 28(3):228-30. PubMed ID: 1906786
[TBL] [Abstract][Full Text] [Related]
17. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions.
Begleiter A; Leith MK
Mol Pharmacol; 1993 Jul; 44(1):210-5. PubMed ID: 8341273
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of BMS-181174. Effects of hypoxia, dicoumarol, and repair deficits.
Rockwell S; Kemple B; Kelley M
Biochem Pharmacol; 1995 Oct; 50(8):1239-43. PubMed ID: 7488240
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck.
Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ
Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546
[TBL] [Abstract][Full Text] [Related]
20. N-[2-(2-methyl-5-nitroimidazolyl)ethyl]-4-(2-nitroimidazolyl)butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug.
Moselen JW; Hay MP; Denny WA; Wilson WR
Cancer Res; 1995 Feb; 55(3):574-80. PubMed ID: 7834627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
